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background: Elevation of cardiac troponin occurs in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac 
outcomes in acute cerebrovascular accident (CVA) remains to be explored.
methods: We performed a retrospective analysis of 566 patients admitted to Temple University hospital from 2008-2010 for acute CVA. Patients 
were included if they had a troponin measured in the first 24 hours, had no evidence of acute coronary syndrome and had an echocardiogram 
performed during that admission. Of 200 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs, EKGs and 
major adverse cardiovascular events during a follow up period up to sixty months (mean±SD: 20.1±20.6). Patients were characterized into two 
groups with normal and elevated troponins (above the normal reference interval 0.05-0.40 ng/ml). The primary end point was non-fatal myocardial 
infarction during follow-up period after discharge. The secondary end points were major adverse cardiac events (MACE) and death from any cause.
results: Of 200 patients, 17 patients had positive troponins. Baseline characteristics were: age 63.1 ± 13.8, 56.5% males, 64% African Americans, 
78% hypertensive, 39.5% diabetics, 22% had history of previous CVA, 7% had atrial fibrillation and 20.5% had history of coronary artery disease, with 
no statistically significant difference between the two groups. 7 patients (41.2%) in the elevated troponin group and 6 (3.3%) patients in normal 
troponin group had a non-fatal myocardial infarction (p=0.0001). MACE (41.2% vs 14.2%, p=0.01) and death from any cause (41.2% vs 14.5%, 
p=0.017) were also significant in the positive troponin group. On logistic regression analysis, positive troponin independently predicted non-fatal MI 
during follow-up after discharge (p=0.004) while elevated CK-MB (p=0.12), prior history of CAD (p=0.79) or new cardiomyopathy (p = 0.789) did not 
predict outcomes.
Conclusions: Elevated troponins in non-ACS setting for patients admitted for acute CVA predict worse cardiovascular outcomes. These patients 
may benefit from closer monitoring and aggressive care after discharge.
